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ABSTRACT
Objective To explore the presentation and 
management of congenital cytomegalovirus (CMV) 
identifi ed through routine clinical investigations, and 
ascertain outcome in early childhood.
Design Active population-based surveillance.
Setting UK and Ireland.
Methods Infants born in 2001–2002 with confi rmed 
or suspected congenital CMV infection were reported 
through the British Paediatric Surveillance Unit, and 
clinicians completed questionnaires on presentation, 
diagnosis, management and subsequent outcome.
Results 86 confi rmed and 70 possible cases of 
congenital CMV infection were reported. Over a third 
(27/72) of singleton infants with confi rmed and 44% 
(27/61) with possible congenital infection were preterm 
(<37 weeks gestation). Among confi rmed cases, 
75% (64/85) presented with neonatal manifestations 
compatible with congenital CMV, over half (34/64) 
of whom had neurological signs; 17 infants were 
treated with gancyclovir. Among confi rmed cases with 
information on outcome, 31% (24/78) were developing 
normally, 18% (14/78) had mild, 24% (19/78) moderate 
and 14% (11/78) severe sequelae, and 13% (10/78) had 
died. Median age at follow-up among survivors was 
18 months (IQR 15–22 months). Children with neonatal 
CMV manifestations were signifi cantly more likely than 
those without to have moderate or severe outcomes 
(including death) (60%, 36/60, vs 22%, 4/18, p=0.001). 
27% of survivors (17/63) had bilateral hearing loss.
Conclusions The number of confi rmed cases of 
diagnosed congenital CMV reported in this study was 
lower than expected, highlighting the need for early and 
appropriate investigations when congenital infection 
is suspected. Due to the unexpectedly high proportion 
of preterm infants, resulting from differential case 
ascertainment, it was diffi cult to distinguish prematurity 
and CMV-related symptoms.
INTRODUCTION
Cytomegalovirus (CMV) is the most common 
congenital infection worldwide. Seroprevalence 
of CMV in women of childbearing age in the UK 
is around 50%, but varies by ethnicity, social class 
and parity.1 Congenital CMV infection can result 
from recurrent (reactivation of latent infection or 
reinfection with a new strain) or primary maternal 
infection in pregnancy.2 3 The birth prevalence of 
congenital CMV in resource-rich countries varies 
according to maternal seroprevalence, and in the 
UK is estimated to be around 3 per 1000.4 5 About 
10–15% of congenitally infected infants are symp-
tomatic at birth,6 and most of these experience 
serious long-term complications, such as cerebral 
palsy, cognitive impairment and sensorineural 
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hearing loss.6–8 In contrast, most asymptomatic 
infants develop normally, although a minority 
(10–15%) develop long-term sequelae, sensorineu-
ral deafness being the most common problem.6 9 
There is some evidence that intravenous gancy-
clovir treatment may improve hearing outcomes 
in severely affected infants;10 11 however, due to 
concerns about toxicity, treatment is currently 
restricted to infants with central nervous system 
involvement.12
CMV is also commonly acquired in infancy, 
mainly through breastfeeding: in one UK study, 
12% of infants born to CMV seropositive moth-
ers acquired infection by 3 months, and 20% by 
1 year.13 Although postnatal acquisition is usu-
ally asymptomatic in term infants, symptomatic 
infection can occur in very preterm infants.14 
Congenital infection is conventionally distin-
guished from postnatal acquisition by virus isola-
tion or DNA from urine or tissue samples collected 
in the ﬁ rst 2–3 weeks of life.15 For infants tested 
after this time, it is often not possible to distin-
guish between congenital and acquired infection, 
although testing stored neonatal dried blood spots 
can be helpful, with test sensitivity ranging from 
71% to 100%.16
Surveillance of congenital CMV was carried out 
in the UK and Ireland, between 2001 and 2003, to 
ascertain the population prevalence of diagnosed 
What is already known on this topic
▶  Congenital cytomegalovirus (CMV) occurs in 
about 3 per 1000 births in the UK and is an 
important cause of deafness and disability in 
children.
▶  Most of the 10–15% of infected infants who 
are symptomatic develop long-term sequelae, 
as do some asymptomatic infants.
What this study adds
▶  Fewer children than expected were reported 
with congenital CMV in this population 
surveillance study, highlighting the diffi culty 
of confi rming congenital infection.
▶  An excess of preterm infants was reported, 
possibly due to opportunistic screening in 
some hospitals.
▶  Forty per cent of children reported with 
congenital CMV had moderate or severe 
outcomes, and 13% died.
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LP, College Station, Texas, USA). Differences in proportions 
were compared using χ2 or Fisher’s exact tests. The annual 
number of live births in England and Wales was obtained from 
Ofﬁ ce for National Statistics data.22
RESULTS
Altogether, 224 paediatricians made 290 reports; 86 infants 
(born to 81 women) had conﬁ rmed congenital CMV, and 70 
were possible cases. Fifty-eight infants were reported in error 
(most born outside the study period (n=31) or with postna-
tally acquired CMV infection). The remaining reports were 
duplicates (n=55) or could not be assessed due to  non-response 
(n=21). Reports of conﬁ rmed and possible cases came from all 
parts of the British Isles, with about a ﬁ fth from the London 
area, and over 60% from elsewhere in England (table 2). 
Seventy-two conﬁ rmed reports were from England and 
Wales (38 in 2001, 34 in 2002), giving an annual prevalence 
of 0.06 per 1000 live births (38/594 634 in 2001, 34/596 122 
in 200222).
Maternal and infant characteristics
Demographic characteristics were similar for conﬁ rmed and 
possible cases (table 2), apart from the proportion of twins: 
15% of conﬁ rmed cases (including ﬁ ve twin pairs), and 7% 
of possible cases (no pairs) were twins. Median maternal age 
was 28 years (IQR 21–32 years for conﬁ rmed cases, n=81 
mothers; IQR 23–33 years for possible cases, n=64 mothers). 
Among the conﬁ rmed singleton cases, 37% (27/72) were pre-
term (<37 weeks gestation), including 15% (11/72) born at <32 
weeks; all 13 twins were preterm, with six born at <32 weeks 
(including two twin pairs). Among possible cases, 44% (27/61) 
of singletons and all ﬁ ve twins were preterm; a third (21/61) of 
singletons and two twins were born at <32 weeks.
Confi rmed cases of congenital CMV
Diagnosis and presentation
Among infants with conﬁ rmed congenital CMV, the ﬁ rst 
available positive test was usually PCR or virus isolation; 88% 
were performed on urine samples (76/86), and 91% (78/86) at 
<7 days of age (table 3).
Three quarters of infants had neonatal symptoms, over half 
with neurological involvement (table 3). Of 21 asymptomatic 
neonates, four had ultrasound abnormalities reported, and the 
mothers of seven had symptoms suggestive of CMV in preg-
nancy, including six with conﬁ rmed seroconversion. Other 
speciﬁ c indications for neonatal testing were reported for 
congenital CMV disease, management strategies and clinical 
disease outcome.17
METHODS
Data collection
The study was carried out through the British Paediatric 
Surveillance Unit (BPSU) of the Royal College of Paediatrics 
and Child Health, an active monthly surveillance system for 
rare conditions of childhood.18 19 Paediatricians were asked 
to report all infants with conﬁ rmed or suspected congenital 
CMV infection born in the UK or Ireland in 2001 or 2002. 
Conﬁ rmed cases were infants with congenital CMV infection 
determined by PCR or virus isolation from urine, blood, saliva 
or tissue taken at biopsy within 3 weeks of birth; suspected 
cases were infants with symptoms compatible with congeni-
tal CMV infection aged under 12 months, with CMV isolated 
after 3 weeks of age. Since there was no national screening 
programme, it was not anticipated that asymptomatic infants 
or those with non-speciﬁ c symptoms at birth would be 
reported. Paediatricians completed standard questionnaires on 
diagnosis, demographic and clinical factors, maternal details, 
treatment and outcome; at least two reminders were sent to 
non-responders. Follow-up information was requested dur-
ing the second or third year of life to establish outcome. All 
diagnoses and investigations were undertaken locally as part 
of routine care.
Case defi nition
For this analysis, congenital CMV infection was deﬁ ned as 
‘conﬁ rmed’ based on a positive PCR, virus isolation or detec-
tion of early antigen ﬂ uorescent foci on a urine, blood, saliva or 
tissue sample taken at <21 days of age.6 Infants reported with 
only a positive IgM result during this period were classiﬁ ed 
as ‘possible’ cases, as were infants with earliest positive CMV 
results on samples taken at 21 days or later. Infants with labo-
ratory evidence of postnatal CMV acquisition were excluded.
Variables
In this paper we describe infants as symptomatic if they had 
one or more of the following neonatal manifestations com-
patible with congenital CMV:6 hepatomegaly, splenomegaly, 
petechiae, thrombocytopenia, chorioretinitis, seizures, intra-
cranial calciﬁ cation or microcephaly (the latter four were also 
classiﬁ ed as neurological signs). The remaining infants are 
described as asymptomatic, even if they had other  non-speciﬁ c 
signs. Microcephaly and small for gestational age were based 
on age- and sex-speciﬁ c z-scores derived from British 1990 
population standards using the LMS method,20 21 and deﬁ ned 
as an occipital-frontal circumference or birth weight below the 
third centile; where these measurements were missing, classi-
ﬁ cation was based on clinical report. Subsequent outcome was 
categorised according to the presence and severity of reported 
sequelae, including hearing or visual impairment, seizures, 
motor or mental impairment or developmental delay. A sum-
mary measure of ﬁ nal outcome for surviving children was 
derived following review of all available information provided 
by clinicians, and classiﬁ ed by the researchers as normal, or 
mild, moderate or severe impairment (see table 1).
Data management and statistical analysis
Data were managed in Access 2003 (Microsoft, Redmond, 
Washington, USA) and analysed using Stata v 11 (StataCorp 
Table 1 Classifi cation of infant outcome
Normal No hearing problems or other impairments reported
Mild impairment Unilateral hearing loss and/or other mild sequelae
 Examples  Unilateral SNHL and mild speech delay
 Congenital heart defect repaired, mild delay
 Mild language/motor/developmental delay
Moderate impairment Bilateral hearing loss and/or other moderate sequelae
 Examples  Profound hearing loss
 Developmental delay and visual problems
 Poor vision, unilateral SNHL, mild developmental delay
Severe impairment Multiple disabilities
 Examples  Cerebral palsy, severe learning diffi culties, bilateral SNHL
 Bilateral SNHL, global delay
 Quadriplegia, blindness, SNHL
SNHL, sensorineural hearing loss. 
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eight additional infants without CMV symptoms or maternal 
indications (table 3). Ultrasound abnormalities or maternal 
symptoms were also reported for 27% (17/64) of symptom-
atic infants. In addition to signs classiﬁ ed as CMV compatible, 
many infants had other non-speciﬁ c signs, for example, jaun-
dice or anaemia. There were no statistically signiﬁ cant dif-
ferences in neonatal presentation between term and preterm 
infants: 69% (31/45) of term infants were symptomatic, and 
82% of preterm infants (33/40, p=0.11); 42% (19/45) and 37% 
(15/40), respectively, had neurological signs (p=0.83).
Eight infants, all symptomatic, died within 8 weeks of birth; 
four had severe complications of prematurity and one a con-
genital syndrome (table 4). Four surviving infants had congeni-
tal abnormalities: cleft palate, positional talipes equinovarus, 
imperforate anus and cleft lip, and atrial septal defect.
Gancyclovir treatment
Seventeen infants with conﬁ rmed infection received intra-
venous gancyclovir, for a median duration of 6 weeks (range 
4 days to 3 months); all but one had neonatal symptoms, includ-
ing 11 with neurological signs (table 5). Treatment was discon-
tinued for three infants due to neutropaenia (after 4 days), 
thrombocytopaenia (after 4 weeks) or abnormal liver function 
tests (after 5 weeks). Six infants with possible congenital CMV 
also received gancyclovir; all presented after 1 month of age 
with either bronchiolitis or pneumonitis.
Outcome
Follow-up information was provided for 89% (70/78) of chil-
dren alive at ﬁ rst report. Two additional deaths were reported, 
both under 12 months of age (table 4); the median age of 
surviving children when last seen was 17.7 months (IQR 14.9–
21.8 months; range 4.2–33.9 months). Among 78 children with 
known outcome, 31% (24/78) were developing normally, 18% 
(14/78) had mild, 24% (19/78) moderate and 14% (11/78) severe 
sequelae, and 13% (10/78) had died. There were no signiﬁ cant 
differences in the proportion of children with moderate or 
worse outcomes according to gestational age: 52% (22/42) of 
term infants, 54% (12/22) of infants born at 32–36 weeks and 
37% (6/16) of those born at <32 weeks had moderate or severe 
outcomes or died (p=0.55). Symptomatic infants were signiﬁ -
cantly more likely than others to have moderate or worse out-
comes (60% vs 22%, p=0.001) and the rate was highest (69%) 
if neurological signs were present neonatally (table 5). Among 
surviving infants, 79% (11/14) of those who received gancy-
clovir had moderate or severe impairment, as did 35% (19/54) 
of those who did not (p=0.006). Hearing problems were 
more common in children with neonatal symptoms (table 
5), although this was not statistically signiﬁ cant (p=0.09). 
Twenty-seven per cent of children had bilateral sensorineural 
Table 2 Demographic and perinatal characteristics of 86 infants* with 
confi rmed and 70 infants with possible congenital cytomegalovirus (CMV) 
infection born in 2001–2002
 
Congenital CMV
Confi rmed cases Possible cases
n (%) n (%)
Region of birth
 London 18 (21) 16 (23)
 England (excluding London) 52 (610) 46 (66)
 Scotland, Wales, Northern Ireland 11 (13)  7 (10)
 Ireland  5 (6)  1 (1)
Twin
 No 73 (85) 65 (93)
 Yes 13 (15)  5 (7)
Sex
 Female 40 (47) 31 (44)
 Male 46 (53) 39 (56)
Ethnic group
 White 65 (76) 44 (64)
 Black 10 (12)  6 (9)
 Other 10 (12) 19 (28)
Parity (mother)
 0 48 (56) 38 (55)
 1 26 (31) 21 (30)
 2+ 11 (13) 10 (14)
Gestational age (completed weeks)
 ≥37 45 (53) 34 (52)
 35–36 16 (19)  5 (8)
 32–34  7 (8)  4 (6)
 <32 17 (20) 23 (35)
*Includes one infant with confi rmed infection but minimal additional information.
Table 3 Indication for testing and neonatal presentation of 86 infants with 
confi rmed congenital cytomegalovirus (CMV) infection born in 2001–2002
 n (%)
Timing of primary CMV test (days of life) (n=86)
 0–2 57 (66)
 3–6 21 (24)
 7–13  3 (3)
 14–20  5 (6)
Type of primary CMV test (n=86)
 PCR 31 (36)
 Virus isolation 31 (36)
 DEAFF 21 (24)
 IgM (confi rmed by PCR on neonatal dried blood spot)  2 (2)
 Histology  1 (1)
Likely indication for CMV testing (n=85)
 Neonatal symptoms compatible with CMV (see below) 64 (75)
 Maternal/antenatal indication 11 (13)
 Other*  8 (9)
 No clear indication  2 (2)
Neonatal symptoms and signs compatible with CMV (n=85)
 No 21 (25)
 Yes, without neurological signs 30 (35)
 Yes, with neurological signs 34 (40)
 Systemic (n=85)
   Hepatomegaly 36 (42)
   Splenomegaly 33 (39)
   Petechiae, purpura 37 (44)
   Thrombocytopenia 50 (59)
 Visual (n=79)
   Chorioretinitis  1 (1)
 Neurological (n=85)
   Seizures  3 (4)
   Intracranial calcifi cation 16 (19)
   Microcephaly (<3rd percentile)† 26 (31)
Small for gestational age (<3rd percentile) (n=85)
 No 58 (68)
 Yes 27 (32)
*Other reasons included severe prematurity (<32 weeks, n=2, one with a 
symptomatic twin), other neonatal symptoms (n=2), small head (although ≥3rd 
centile, n=2) and HIV-infected mother (n=2).
†16 infants were microcephalic and small for gestational age.
DEAFF, detection of early antigen fl uorescent foci. The primary CMV test was the 
fi rst available positive test.
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hearing loss (table 5), including four reported to have had 
cochlear implants.
Possible congenital CMV
Among 70 infants with possible congenital CMV, three had 
unconﬁ rmed positive IgM results in the ﬁ rst 3 weeks of life. 
First available CMV test samples were taken at a median 
age of 65 days (range 0–264 days; IQR 35–107 days). A third 
(24/70) of these infants had neonatal symptoms compatible 
with congenital CMV, over half (13/24) of whom had neuro-
logical signs. Eleven infants died, at median age of 2.7 months 
(range 13 days to 9.5 months): nine were very preterm (<32 
weeks, including six <28 weeks), one was reported as a sud-
den infant death and one died of respiratory and cardiac fail-
ure. Among surviving children with outcome information 
available, over half (32/56) were developing normally and 
23% (13/56) had moderate or severe outcomes. Median age 
at follow-up was 20.4 months (IQR 11.4–28.1 months).
DISCUSSION
This observational surveillance study highlighted important 
issues relating to ascertainment of congenital CMV infec-
tion. We sought notiﬁ cation of infants with conﬁ rmed or 
suspected congenital CMV identiﬁ ed through routine inves-
tigations, and expected reports of infants presenting with 
manifestations of CMV disease. However, infants without 
typical CMV symptoms were also reported, and almost half 
of conﬁ rmed and suspected cases were preterm. In a similar 
Australian surveillance study, only 9% of reported infants 
were preterm (<36 weeks),23 and congenital CMV is not an 
established risk factor for preterm birth.24 This excess of 
preterm infants could be due to differential case ascertain-
ment arising from opportunistic screening policies; indeed, 
one respondent reported a local CMV screening policy for 
babies admitted to the special care unit. Case classiﬁ cation 
was particularly challenging, as in preterm infants it was dif-
ﬁ cult to differentiate symptoms compatible with CMV from 
those of prematurity. Furthermore, test results were some-
times inadequate and/or too late to distinguish congenital 
from postnatal infection. Symptomatic CMV disease fol-
lowing postnatal infection is more likely in low birthweight 
infants,14 and could have contributed to the high proportion 
of preterm infants among the possible cases. However, the 
natural history of early postnatal CMV acquisition remains 
poorly understood.25
Table 5 Treatment and clinical outcome according to neonatal presentation
 
 
Neonatal manifestations 
compatible with congenital 
cytomegalovirus
Total No
Yes, 
non-neuro
Yes, 
neuro
n (%) n (%) n (%) n (%)
Treatment (n=85)
 No 68 (80) 20 (95) 25 (83) 23 (68)
 Yes 17 (20)  1 (5)  5 (17) 11 (32)
Summary outcome (n=78)
 Normal 24 (31) 13 (72)  6 (21)  5 (16)
 Mild 14 (18)  1 (6)  8 (29)  5 (16)
 Moderate/severe/died 40 (51)  4 (22) 14 (50) 22 (69)
Hearing (n=63)*
 Normal 34 (54) 13 (76) 10 (40) 11 (52)
 Unilateral/mixed hearing loss 12 (19)  1 (6)  8 (32)  3 (14)
 Bilateral sensorineural hearing loss 17 (27)  3† (18)  7 (28)  7 (33)
*Excludes 10 children who died.
†All term infants, one small for gestational age, one borderline microcephalic (4th 
centile).
Neuro, neurological symptoms.
Table 4 Details of 10 children with confi rmed congenital cytomegalovirus (CMV) reported to have died
Case
Gestational 
age (weeks) Birth weight (g)
Age at death 
(weeks) Treatment Neurological signs Additional details
1 27 <1000 <1 No IC Complications of 
prematurity, hepatic 
calcifi cation
2 37 1500–2499 <1 No IC+microcephaly Severe CMV symptoms
3 38 1000–1499 <1 No Ventriculomegaly Septicaemia, calcifi ed 
placenta
4 38 >2500 <1 No Microcephaly Erythroblastosis 
fetalis, severe CMV 
symptoms
5 29 <1000 2–8 <2 weeks IC+microcephaly+other Complications 
of prematurity, 
ventriculomegaly, 
seizures
6 30 <1000 2–8 No Microcephaly Complications of 
prematurity
7 35 1500–2499 2–8 No Seizures Patau syndrome
8 39 1500–2499 2–8 No IC+microcephaly Multiple CMV 
symptoms, bilateral 
hearing loss
9* 24 <1000 >8 6 weeks Microcephaly Pneumonia, chronic 
lung disease, oedema, 
complications of 
prematurity
10* 34 1500–2499 >8 6 weeks Ventriculomegaly Respiratory failure 
(pneumonia)
*Death reported at follow-up.
IC, intracranial calcifi cations.
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This study was carried out through the BPSU, a well estab-
lished active surveillance system, relying on clinical diagno-
sis through routine investigations. Overall, we identiﬁ ed 86 
infants with conﬁ rmed congenital CMV born in 2001–2002, 
a reported prevalence of diagnosed congenital CMV (0.06 per 
1000 live births) more than sixfold lower than expected if 
actual prevalence was 3 per 1000 births,4 with 10–15% symp-
tomatic at birth.6 This low case ascertainment is probably due 
to the non-speciﬁ c clinical presentation of congenital CMV, 
and the delay in taking appropriate samples early in life, as 
well as to under-reporting.
A further 70 infants suspected by clinicians of having 
congenital infection lacked conﬁ rmatory tests in the ﬁ rst 
3 weeks of life and were classiﬁ ed as possible cases. This 
group is likely to have included both infants with congeni-
tal infection and those with early-acquired postnatal infec-
tion. Although TORCH screening (for toxoplasmosis, rubella, 
CMV and herpes simplex virus) has been discouraged over 
the last 20 years,26 27 this was speciﬁ ed in some reports with 
positive IgM, and results were not always followed up with 
appropriate and timely conﬁ rmatory tests. There is clearly 
a need for robust testing protocols when congenital CMV is 
suspected, ideally, viral culture or PCR on saliva or urine in 
the ﬁ rst 2–3 weeks of life.12 Retrieval and testing of neonatal 
dried blood spots can also assist in the retrospective diagnosis 
of congenital CMV, but sensitivity can vary.16 28–30 In an exer-
cise reported elsewhere, only 75% of blood spots retrieved for 
conﬁ rmed cases in this study were positive.28
Almost half of the children in this study had serious dis-
abling conditions or died, and almost a third of survivors had 
bilateral sensorineural hearing loss at a median follow-up age 
of 18 months. Despite study differences in deﬁ nitions and 
case ascertainment, outcomes were similar to those reported 
elsewhere. For example, among children with neonatal symp-
toms, 32% had bilateral hearing loss, consistent with rates of 
30–40% reported in the literature.31 Cases of late-onset hear-
ing loss, which have been reported in other studies,32–34 could 
have been missed in this study due to the limited duration 
of follow-up. The proportion of symptomatic neonates with 
moderate or severe outcomes (about half) was comparable to 
the estimated 40–58% reported in a recent meta-analysis.8 
However, we could not assess the extent to which neonatal 
manifestations or reported sequelae were affected by com-
plications of prematurity or other underlying conditions. 
We were also unable to assess the effectiveness of gancyclo-
vir treatment due to the lack of controls and selective use of 
treatment.
The children reported to this study were a subset of those 
born with congenital CMV in 2001 and 2002, and did not 
include those who were asymptomatic in infancy but devel-
oped late-onset sequelae. The true burden of disease associ-
ated with congenital CMV remains unknown. Nevertheless, 
the poor outcomes observed highlight the need for safe and 
effective treatment for congenitally infected infants. In light 
of recent advances in antiviral therapy for CMV,35 there is an 
urgent need to identify those children most likely to beneﬁ t 
from treatment in the future.
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